Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort

Cavitary pulmonary tuberculosis (TB) is known to remain its Infectivity for a longer period of time than the non-cavitary pulmonary TB, which is usually almost inactivated its infectivity within two weeks after the administration of the anti - TB drugs.

However, there are few studies on this, so it is not known how long the infectivity persists, whether there is a correlation with the number of cavities or the size of the cavities between persistence of infectivity.

Meanwhile, endobronchial TB is known also to be highly infectious, unlike simple pulmonary TB.

It is not known how long infectivity can persist after the administration of anti-TB medication, and whether there is any difference in persistence of infectivity regarding the clinical characteristics of endobronchial TB.

In this study, investigators will analyze the retrospective data analysis of UUH-PPM Cohort, a cohort of PPM project patients in the Ulsan University Hospital (UUH).

The PPM project is a "Private-Public Mix project" for the eradication of tuberculosis from Korea, which the Korean government and private medical institutions have been conducting since 2007.

A. Cavitary Pulmonary TB Group

Inclusion criteria

• Aged 18 years and older
• The patient who has the cavitary pulmonary TB

Exclusion criteria

• Age < 18 years
• Any Malignant patient
• Patients with bacterial or viral or fungal pneumonia based on the judgment of the attending physician
• Patients who had a history of any pulmonary cystic lesion such as infected bulla, bullous emphysema
• Patients who were diagnosed with pulmonary fungal infection or previous its history or any documented culture of the fungus from a bronchial sample including sputum
• Patients who were diagnosed with bronchiectasis
• Patients who were diagnosed with NTM-PD (non-tuberculous mycobacterial pulmonary disease) or any documented culture of NTM from a bronchial sample including sputum
• Patients who were diagnosed with connective tissue disease such as Wegener's granulomatosis, SLE
• Patients who were diagnosed with TB destroyed lung
• Patients who were diagnosed with congenital lung disease such as Congenital Cystic Adenomatoid Malformation (CCAM), pulmonary sequestration
• Patients who were diagnosed with interstitial lung disease such as Lymphangioleiomyomatosis (LAM), idiopathic pulmonary fibrosis (IPF)
• Patients who were diagnosed with culture-negative pulmonary TB
• Patients who did not take anti-TB medication more than twice a week on average
• Patients who were diagnosed with sarcoidosis
• Patients who were diagnosed with paragonimiasis
• Patients who were diagnosed with pulmonary thromboembolism due to excluding pulmonary infarction
• The patient who did not consent
• Patients who were diagnosed with MDR/XDR TB through AFB culture

B. Endobronchial TB Group

Inclusion criteria

• Aged 18 years and older
• The patient who has the endobronchial TB through bronchoscopy

Exclusion criteria

• Age < 18 years
• Patient who was not consented